Top 5 bladder cancer articles of 2019

The BCG shortage, overuse of cystoscopy, and hematuria evaluation approaches are among the topics of the most-read Urology Times articles from 2019 on bladder cancer.

Related Videos

Related Content

Advertisement

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

March 29th 2022

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Urology Times staff

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

Related Content

Advertisement

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

March 29th 2022

Destigmatizing Urology: Dr. Pettaway discusses penile cancer

Urology Times staff

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.